Original Research Article

Association of c-reactive protein and lipid accumulation product with fasting insulin levels in obese first degree relatives of type-2 diabetics

Sonia Chawla1,*, Gitanjali1, Seema Bhatti2, Sarita3, Navneet Kaur1, Jaswant Kaur4

1Dept. of Biochemistry, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
2Dept. of Gynaecology and Obstetrics, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
3Dept. of Pathology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
4Dept. of Biochemistry, NC Medical College and Hospital, Panipat, Haryana, India

A R T I C L E   I N F O

Article history:
Received 06-12-2020
Accepted 18-12-2020
Available online 21-01-2021

Keywords:
Type 2 diabetes mellitus
Lipid accumulation product
C reactive protein
Metabolic syndrome

A B S T R A C T

The obese first degree relatives of type 2 diabetics are more prone to develop diabetes mellitus in later life. Having one parent with type 2 diabetes mellitus carries 1.6 fold and both the parents with type 2 diabetes mellitus (T2DM) has 3.2 fold higher risk of developing T2DM. Lipid accumulation product (LAP) is a simple and reliable index of central lipid accumulation. It combines waist circumference and triacylglycerols. Studies have revealed that LAP is a better indicator than Body mass index (BMI) in predicting risk of diabetes mellitus and metabolic syndrome. Weight gain and body mass are the main factors in increasing risk for diabetes mellitus. Fat cells produce chemicals (inflammatory markers) that cause inflammation. Internal inflammation can also leads to the development of diabetes mellitus. C reactive protein (CRP) is an inflammatory marker produced by liver cells. Studies have shown that elevated CRP is linked to higher risk of developing diabetes in later life. In this study, we have found an association of Serum Insulin (SI), LAP and CRP in first degree relatives of type-2 diabetics. We had taken 100 Obese first degree relatives of type-2 diabetics as subjects and 100 age and sex matched first degree relative of T2DM without obesity were taken as controls. Fasting blood glucose, Fasting TGs estimations were done using fully autoanalyser. Waist circumference (in cm) was measured and also LAP score was calculated by using the formula, i.e. (WC-58)*TG mmol/l & (WC-65)*TG mmol/l in females and males respectively. CRP was estimated using Nyco-card reader. Serum Insulin was measured using ELISA reader. The Mean ±SD of Serum Insulin, CRP, LAP, FBS in Group I were found to be 15.9±2.54, 6.05±1.5mg%, 106.8±40.7, 133.0±18.9 mg% respectively compared to Group II 9.2±1.28, 2.59±1.2, 25.7±14.6, 78.7±8.2. A highly significant correlation of LAP and CRP (p<0.01) was found in study group. A significant correlation of Serum Insulin (SI), CRP and LAP score (p<0.05) was found. This study suggested that first degree relatives of type-2 diabetics should have some modification in their lifestyle as they are at increased risk of metabolic syndrome, diabetes and coronary artery disease.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

The prediction that over 366 million people worldwide will suffer from Type 2 Diabetes Mellitus (DM) by 2030 has become a worldwide concern.1 It is a multifactorial disease presenting with chronic hyperglycemia. The metabolic derangements occur sometimes before onset of diabetes. Through unresolved mechanisms, genetic predisposition, ethnicity, changes in BMI, lipid profile are contributing to its pathogenesis.2 Growing evidences have shown that the first degree relatives (FDR) of patients with T2DM are more susceptible to develop insulin resistance and defects in insulin secretion.3 FDR can be described as having a parent, sibling or child with T2DM. There is a strong connection between BMI, Lipids (TGs and TCs) and diabetes in FDR of T2DM. 4 It is accepted that...
dyslipidemia, raised TGs and TCs affect β-cell function in diabetes mellitus. Prolonged TGs exposure leads to a chronic phase associated with loss of β-cell function and impaired glucose tolerance. LAP an index of central lipid adiposity has been proposed as a reliable risk indicator of insulin resistance, metabolic syndrome, cardiovascular diseases and diabetes mellitus. It also has a relation with visceral adiposity. The use of TG levels in combination with waist circumference termed as hyper triglyceridemic waist is able to find individuals with highest amount of visceral fat. The higher LAP in healthy individuals is associated with abnormal glucose homeostasis and insulin resistance. Underlying low grade inflammation with raised visceral adipocytes contribute to increased levels of several inflammatory proteins such as CRP, IL-6, and PAL. Underlying low grade inflammation with raised production of proteins associated with inflammation leads to T2DM. CRP levels are regulated by interleukin-6 and TNF-α produced by adipocytes. The mechanism of association between CRP and T2DM is not clear. Some factors like oxidative stress can also lead to low grade inflammation and genetic predisposition might lead to T2DM. Elevated CRP might induce insulin resistance by increasing thrombogenic agents, stimulating complement cascade, increasing expression of endothelial adhesion molecules (EAM).

2. Aims and Objectives

The present study was aimed to find association of CRP and LAP with Fasting Insulin levels in obese first degree relatives of type 2 diabetics.

3. Materials and Methods

3.1. Study population

The study was performed in Department of Biochemistry in Guru Gobind Singh Medical College and Hospital, Faridkot. Data was collected through questionnaires. Inclusion criteria for study participation included: 1) First degree relatives of patients with Type 2 Diabetes Mellitus aged 30 to 70 years having simple obesity through physical examination (2) BMI greater than 25 kg/m² for obese; (3) participants must have stable body weight for at least three months prior to study (4) no weight loss by taking any dietary plans.

Based on the above criteria, 100 obese first degree relatives of type 2 diabetics were selected to participate in the study. Informed consent was taken. 100 age and sex matched first degree relative of T2DM without obesity were taken as controls.

3.2. Anthropometric measurements

The height was measured with wall mounted stadiometer. Weight was also assessed using a weighing machine. Body mass index (BMI) was calculated using the weight and height measurements. Waist circumference measurements were taken at the mid-point between the bottom rib and the hip bone.

3.3. Lab data

Overall 10 hr fasting sample was taken to measure blood glucose, triglycerides and Fasting insulin. Blood glucose was measured by using fully auto analyser. Serum LDL cholesterol was calculated using Friedewald’s equation, except for triglycerides > 400 mg/dL. Moreover, Serum insulin was determined using an enzyme-linked immunosorbet assay (ELISA). The sensitivity of the assay was 1.5 μU/ml and the coefficient variation for inter-assay and intra-assay were 6.29 and 7.67% respectively. CRP was measured using Nyco card reader. LAP was measured using formula: (WC-58)*TG mmol/l & (WC-65)*TG mmol/l in females and males respectively.

Statistical analysis was performed using SPSS.

3.4. Cut off values

Serum Insulin >12μIU/L was considered as insulin resistant. Normal value of Insulin is upto <9μIU/L. C-reactive protein of 5 mg% were considered as normal. LAP cut off values in our population (cm·mmol/L) for males were, 65.8 and 103.4 (range: 21.6–247.9); females, 44.7 and 81.5 (range: 11.6–215.4).

4. Results

In the study population, the mean fasting blood glucose was higher than the control group. The average values of most of the parameters were higher in study group I. (Table 1)

Table 1: Showing basic characteristics of both the groups

| Characteristics       | Group I Mean ±SD | Group II Mean ±SD |
|-----------------------|------------------|-------------------|
| Fasting Blood Glucose | 133.0±18.9       | 78.7±8.2          |
| BMI (kg/m2)           | 27.09±10.62      | 21.29±2.44        |
| Total cholesterol (mg/dL) | 220.2±6.6     | 150.2±8.6         |
| LDL cholesterol (mg/dL) | 147.2±7.2      | 128.2±9.6         |
| Fasting insulin (U/L) | 15.9±2.54        | 9.2±1.28          |
| C Reactive Protein    | 6.05±1.5         | 2.59±1.2          |
| LAP                   | 106.8±40.7       | 25.7±14.6         |

A highly significant correlation of LAP and CRP (p<0.01) was found in study group. A significant correlation
of Serum Insulin (SI), CRP and LAP score with FBS (p<0.05) was found. Also, Figures 1, 2 and 3 shows the correlations between LAP, CRP and Insulin. Overall this present study, suggested that obese FDR of T2DM shows more insulin resistance and inflammation which can further be the underlying factor predisposing to it.

Fig. 1: Correlation between LAP and Insulin in FDR T2DM

![Fig. 1](image1.png)

Fig. 2: Correlation between CRP and Insulin in FDR of Type2 DM

![Fig. 2](image2.png)

5. Discussion

In the present study, we have chosen FDR of T2DM as they are at increased risk of developing T2DM due to genetic predisposition and obesity. We have showed the association of LAP and CRP with fasting insulin and blood glucose levels in obese first degree relatives of type-2 diabetics. LAP and CRP are reliable predictors of risk of diabetes. They have shown a correlation with insulin resistance.

In the current study, LAP index was related to higher fasting insulin and blood glucose values showing insulin resistance in FDR T2DM group. Our results are supported by some studies. Kan Sun et al. has recently found relatively stronger association of LAP than other adiposity parameters with increased measures of Insulin resistance and diabetes mellitus. A strong association of LAP with fasting plasma glucose, glycosylated hemoglobin and fasting insulin was also found. Moreover another study found that obese FDR of T2DM with elevated triglycerides (a component of LAP) levels had HOMA 2-IR score indicating some degree of insulin resistance.

We examined the relationship between CRP, Fasting insulin and found more insulin levels than non obese FDR of T2DM. Suganya et al. found an association of CRP concentrations with increased risk of developing T2DM. Various other recent studies are supporting association of CRP with risk of developing diabetes mellitus. Another study had revealed that increase in CRP is strongly associated with risk of type-2 diabetes compared with subjects with a low level among both men (P = 0.028) and women (P = 0.004). CRP plasma levels were significantly higher in subjects with family history than subjects without family history. Moreover, they found an independent association of CRP with age, family history, body mass index, waist circumference, and HOMA IR.

A correlation between LAP and CRP was also found confirming the fact that adipocyte produce inflammatory proteins such as CRP, IL-6, P-selectin contributing to underlying inflammation that may be a contributor to insulin resistance. The markers are unique in sense because both the markers are easy to perform. LAP combines Waist circumference and TG levels. Due to stability in plasma and serum, established standards have made CRP, a reliable marker of inflammation. We used fasting Insulin for assessing risk of insulin resistance in obese people. Another study suggested that fasting insulin (FI) is sensitive and reliable marker in detecting Insulin resistance in obese people. So, FI can be used as an easy test to detect IR in obese people.

The present study has some limitations such as small sample size. So, further studies with more sample size should be done to establish association of LAP and CRP with risk of
developing diabetes in FDR of T2DM.

6. Conclusion

LAP and CRP has shown to be reliable indicators of incidence of diabetes in FDR T2DM. These simple tests may help in clinical settings to identify individuals at increased risk of T2DM.

7. Source of Funding

None.

8. Conflict of Interest

The authors declare no conflict of interest.

References

1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53. doi:10.2337/diacare.27.5.1047
2. Ragsado ET, Porchia LM, Ruiz-Vivanco G, González-Mejía ME. Obese First-Degree Relatives of Patients with Type 2 Diabetes with Elevated Triglyceride Levels Exhibit Increased b-Cell Function and metabolic syndrome and related disorders. Metab Syndr Relat Disord. 2015;13(1). doi:10.1089/hsy.2014.0028
3. Baez-Duarte BG, Sanchez-Guillenmed C, Perez-Fuentes R. Beta-cell function is associated with metabolic syndrome in Mexican subjects. Diabetes Metab Syndr Obes. 2010;3:301–9.
4. Bardini G, Dicembrini I, Pala L, Cresci B, Rotella CM. Hypertriglyceridaemic waist phenotype and ß-cell function in subjects with normal and impaired glucose tolerance. Diabetic Med. 2011;28(10):1229–33. doi:10.1111/dme.12052
5. Lingvay I, Szczepaniak EW, Szczepaniak LS. Ethnic diversity in beta-cell function susceptibility to pancreatic triglyceride levels: Pilot investigation. J Diabetes Metab. 2014;5:348.
6. Lopez S, Bermudez B, Pacheco YM. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: Monounsaturated compared with saturated fatty acids. Am J Clin Nutr. 2008;88:638–44.
7. Wakabayashi I, Daimon T. A Strong Association between Lipid Accumulation Product and Diabetes Mellitus in Japanese Women and Men. J Atheroscler Thromb. 2014;21(3):282–8. doi:10.5551/iat.20128
8. Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z. Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Exp Clin Endocrinol Diabetes. 2013;121(02):115–8. doi:10.1155/2011/623076
9. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
10. Chiang JK, Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovasc Disord. 2012;12(1):78. doi:10.1186/1471-2261-12-78
11. Sam S, Hoffner S, Davidson MH, D’Agostino R, Feinstein S, Kondos G, et al. Hypertriglyceridemic Waist Phenotype Predicts Increased Visceral Fat in Subjects With Type 2 Diabetes. Diabetes Care. 2009;32(10):1916–20. doi:10.2337/dc09-0585
12. Oh JY, Sung YA, Lee HJ. The lipid accumulation product as a useful index for identifying abnormal glucose regulation in young Korean women. Diabetic Med. 2013;30(4):436–42. doi:10.1111/dme.12114
13. Calabrò P, Golia E, Maddalone V, Malvezzi M, Casillo B, Marotta C. Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med. 2009;4(1):25–34. doi:10.1007/s11739-008-0172-6
14. van Woudenbergh G, Knijsten A, Sijbrands EJG, Hofman A, Witterman JCM, Feskens EJM. Glyceremic Index and Glyceremic Load and Their Association with C-Reactive Protein and Incident Type 2 Diabetes. J Nutr Metab. 2011;2011:1–7. doi:10.5171/2011.06177
15. Freeman DJ. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of scotland coronary prevention study. Diabetologia. 2002;51:1596–1600.
16. Kim DJ. Te epidemiology of diabetes in Korea. Diabetes Metab J. 2011;35:303–8.
17. Fukuchi Y. Immunohistochemical detection of oxidative stress biomarkers, Dityrosine&N(epsilon)-(hexanoyl)lysine & CRP in rabbit atherosclerotic lesions. J Atheroscler. 2008;15:185–92.
18. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: Targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8–11. J Immunol. 1999;163:3957–62.
19. Sun K. Assessment of adiposity distribution and its association with diabetes and insulin resistance: a population-based study. Diabetol Metab Syndr. 2019;11:51.
20. Kamarni S, Kwon M, Shin MK, Kim MK. Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study. Sci Rep. 2019;9(1):4573. doi:10.1038/s41598-019-40987-8
21. Nakashiw S, Yamane K, Kamei N, Okubo M, Knoho N. Elevated C-Reactive Protein Is a Risk Factor for the Development of Type 2 Diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7. doi:10.2337/diacare.26.12.2754
22. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52(7):1799–1805.
23. Liu S. A prospective study of inflammatory cytokines and diabetes mellitus in a multietnic cohort of postmenopausal women. Arch Med Sci. 2007;26:1656–7.
24. Nakashiw S, Okubo M, Yamane K, Knoho N, Kamei N. Elevated C-Reactive Protein Is a Risk Factor for the Development of Type 2 Diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7.
25. Pannaculli N, Pergola GD, Giorgino F, Giorgino R. A family history of type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. Diabet Med. 2002;19(8):689–92.
26. Panag K, Kaur N, Goyal G. Correlation of insulin resistance by various methods with fasting insulin in obese. Int J Appl Basic Med Res. 2014;4(3):41–5. doi:10.1111/jabm.12071

Author biography

Sonia Chawla, Ph.D Research Scholar

Gitanjali, Professor and Head

Seema Bhatti, Professor and Head

Sarita, Professor and Head

Navneet Kaur, PhD Research Scholar

Jaswant Kaur, Assistant Professor

Cite this article: Chawla S, Gitanjali, Bhatti S, Kaur N, Kaur J. Association of c-reactive protein and lipid accumulation product with fasting insulin levels in obese first degree relatives of type-2 diabetics. Int J Clin Biochem Res 2020;7(4):466–469.